Clinically Relevant Subgroups News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV’s Lead Immunotherapy to be Investigated in Breast Cancer
May 10, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 10, 2021
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound, maveropepimut-S (DPX-Survivac) will be investigated in patients with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer. HR+/HER2- tumors represent an unmet clinical need with relatively poor responses to neoadjuvant endocrine treatment 1. This investigator-initiated clinical study will be conducted at the Providence Cancer Institute in Portland, Oregon, and is expected to begin during summer 2021. ....

United States , Kristinah Young , Sashae Stanton , Merck Keytruda , Relationsmarc Jasmin , Cancer Immunoprevention Lab At Providence , National Cancer Institute , Joseph Health , Earlea Chiles Research Institute , Tumor Microenvironment Lab , Robertw Franz Cancer Center , European Medicines Agency , Providence Cancer Institute , Providence Cancer Institute In Portland , Frederic Ors , Chief Executive Officer , Assistant Member , Research Institute , Cancer Immunoprevention Lab , Fast Track , Orphan Drug , Cancer Institute , Cancer Center , Based Treatments , Clinically Relevant Subgroups , Negative Metastatic Breast Cancer ,